Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Why Pfizer (PFE) Stock Is Trading Up Today

PFE Cover Image

What Happened?

Shares of global pharmaceutical company Pfizer (NYSE: PFE) jumped 5.9% in the afternoon session after the company reached an agreement with the U.S. government to lower drug prices and reported positive trial data for a weight-loss drug from a recently acquired company. 

The drugmaker voluntarily agreed to reduce prices for certain medications through Medicaid and sell them directly to consumers on a new platform, TrumpRx. As part of the deal, Pfizer also committed to investing $70 billion in domestic research, development, and manufacturing. Separately, Metsera, an obesity-focused startup that Pfizer is in the process of acquiring for $4.9 billion, announced promising results from a mid-stage trial. Its experimental weight-loss drug demonstrated a mean weight loss of up to 14.1% in patients, which likely added to investor optimism.

Is now the time to buy Pfizer? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Pfizer’s shares are not very volatile and have only had 2 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

The previous big move we wrote about was 18 days ago when the stock dropped 3.5% on the news that reports revealed federal health officials are planning to link COVID-19 vaccines to the deaths of children. 

The decline followed a Washington Post story stating that officials intend to present data to advisors for the Centers for Disease Control and Prevention (CDC) connecting the vaccines to 25 child deaths. This development has heightened investor concerns about vaccine manufacturers, including Pfizer, BioNTech, and Moderna, which also saw their shares fall. The negative sentiment builds on recent headwinds for the sector, as the Food and Drug Administration (FDA) imposed new restrictions in late August, limiting the next round of vaccines to people over 65 or those with qualifying health conditions.

Pfizer is down 5.1% since the beginning of the year, and at $25.25 per share, it is trading 16.4% below its 52-week high of $30.19 from October 2024. Investors who bought $1,000 worth of Pfizer’s shares 5 years ago would now be looking at an investment worth $688.10.

Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.